Skip to main content

Advertisement

SpringerLink
Log in

The economic burden of osteoporosis in Iran in 2020

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

Osteoporosis, the most common metabolic bone disease, leads to increased susceptibility to fractures. In 2020, about 150,000 osteoporotic fractures occurred in Iran. Osteoporosis and related fractures cost the community US$ 393 million.

Introduction

The present study aimed at estimating the economic burden of osteoporosis in Iran in 2020.

Methods

We estimated the annual economic burden of osteoporosis in the above 50 years old population using a prevalence-based approach and from a societal perspective. The incidence of osteoporosis and related fractures were estimated based on meta-analysis reports in Iran and international comparisons. The direct medical and non-medical costs as well as the monetary value of quality-adjusted life-years (QALYs) lost because of fractures were estimated. Cost data were extracted from patient records, medical services prices, and previous literature.

Results

A total of 154,530 osteoporotic fractures were estimated in Iran in 2020. The shares of the hip, vertebral, forearm, and other fractures were 14%, 15%, 17%, and 54%, respectively. There were also 3554 deaths from osteoporotic fractures. The economic burden of osteoporosis in Iran was estimated at US$ 393.24 million (US$ 2165 million purchasing power parity 2020). Direct medical and non-medical cost (47.44%), QALY loss (29.65%), and long-term care for prior hip fracture costs (9.4%) were the main component of the economic burden of osteoporosis.

Conclusion

The economic burdens of osteoporosis are significant in Iran. Interventions to prevent osteoporosis and especially associated fractures, such as screening and prophylaxis, can reduce the cost of the disease and improve patients’ quality of life. Further studies are needed to identify cost-effective and feasible interventions in Iran.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Tootee A, Larijani B (2019) World osteoporosis day: celebrating two decades of progress in preventing osteoporotic fractures in Iran. J Diabetes Metab Disord 18(2):725–727

    Article  Google Scholar 

  2. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. The Lancet 377(9773):1276–1287

    Article  CAS  Google Scholar 

  3. International osteoporosis foundation (IOF). What is osteoporosis. https://www.osteoporosis.foundation. Accessed 2021

  4. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 8(1):1–115

    Google Scholar 

  5. Curtis EM, Moon RJ, Harvey NC, Cooper C (2017) Reprint of: The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Int J Orthop Trauma Nurs 26:7–17

    Article  Google Scholar 

  6. Pennestrì F, Corbetta S, Favero V, Banfi G (2019) Fragility fracture prevention—implementing a fracture liaison service in a high volume orthopedic hospital. Int J Environ Res Public Health 16(24):4902

    Article  Google Scholar 

  7. Salari N, Ghasemi H, Mohammadi L, Rabieenia E, Shohaimi S, Mohammadi M (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16(1):1–20

    Google Scholar 

  8. International osteoporosis foundation (IOF). About osteoporosis. https://www.osteoporosis.foundation/patients/about-osteoporosis. Accessed July 2019

  9. Irani AD, Poorolajal J, Khalilian A, Esmailnasab N, Cheraghi Z (2013) Prevalence of osteoporosis in Iran: a meta-analysis. J Res Med Sci 18(9):759–766

    PubMed  PubMed Central  Google Scholar 

  10. Wong RM, Law S, Lee K, Chow SK, Cheung W (2019) Secondary prevention of fragility fractures: instrumental role of a fracture liaison service to tackle the risk of imminent fracture. Hong Kong Med J 25(3):235–242

    Article  CAS  Google Scholar 

  11. Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. British medical bulletin. 2020

  12. Briot K (2017) Fracture liaison services. Curr Opin Rheumatol 29(4):416–421

    Article  Google Scholar 

  13. Tarride J-É, Adachi J, Brown J, Schemitsch E, Slatkovska L, Burke N. Incremental costs of fragility fractures: a population-based matched-cohort study from Ontario, Canada. Osteoporosis International. 2021:1–9

  14. Marcellusi A, Rotundo MA, Nardone C, Sciattella P, Gazzillo S, Rossini M et al (2020) Osteoporosis: economic burden of disease in Italy. Clin Drug Investig 1–10

  15. Mosadeghrad AM, Mousavi A (2021) The futurology of aging population in Iran: Letter to the Editor. Tehran Univ Med J 68(3):66–71

    Google Scholar 

  16. Tanha K, Fahimfar N, Nematollahi S, Sajjadi-Jazi SM, Gharibzadeh S, Sanjari M et al (2021) Annual incidence of osteoporotic hip fractures in Iran: a systematic review and meta-analysis. BMC Geriatr 21(1):1–8

    Article  Google Scholar 

  17. Kanis J, Johnell O, Oden A, Sernbo I, Redlund-Johnell I, Dawson A et al (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11(8):669–674

    Article  CAS  Google Scholar 

  18. Iranian Statistics Center. Statistics-by-Topic/Population: definitions, concepts and statistical survey. https://www.amar.org.ir/english/Statistics-by-Topic/Population. Accessed 2022

  19. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. The Lancet 353(9156):878–882

    Article  CAS  Google Scholar 

  20. Johnell O, Kanis J, Odén A, Sernbo I, Redlund-Johnell I, Petterson C et al (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15(3):175–179

    Article  CAS  Google Scholar 

  21. Johnell O, Kanis J, Oden A, Sernbo I, Redlund-Johnell I, Petterson C et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38–42

    Article  CAS  Google Scholar 

  22. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108–112

    Article  Google Scholar 

  23. Gauthier A, Kanis JA, Jiang Y, Martin M, Compston JE, Borgström F, et al (2011) Gauthier, A., et al., Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. Arch Osteoporos 6(1):179–88

  24. Tosteson A, Jönsson B, Grima D, O’Brien B, Black D, Adachi J (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12(10):849–857

    Article  CAS  Google Scholar 

  25. Zethraeus N, Borgström F, Ström O, Kanis J, Jönsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int 18(1):9–23

    Article  CAS  Google Scholar 

  26. World Health Organization, Global Health Observatory data repository, Life tables by country. http://apps.who.int/gho/data/node.main.LIFECOUNTRY?lang=en. Accessed 2017

  27. Jönsson B, Ström O, Eisman JA, Papaioannou A, Siris ES, Tosteson A et al (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967–982

    Article  Google Scholar 

  28. Borgström F, Sobocki P, Ström O, Jönsson B (2007) The societal burden of osteoporosis in Sweden. Bone 40(6):1602–1609

    Article  Google Scholar 

  29. Rajabi M, Ostovar A, Sari AA, Sajjadi-Jazi SM, Fahimfar N, Larijani B et al (2021) Direct costs of common osteoporotic fractures (hip, vertebral and forearm) in Iran. BMC Musculoskelet Disord 22(1):1–7

    Article  Google Scholar 

  30. Stevenson M, Davis S, Kanis J (2006) The hospitalisation costs and out-patient costs of fragility fractures. Women’s Health Med 3(4):149–151

    Article  Google Scholar 

  31. Dyer SM, Crotty M, Fairhall N, Magaziner J, Beaupre LA, Cameron ID, et al (2016) A critical review of the long-term disability outcomes following hip fracture. BMC Geriatr 16(1):1–18

  32. Brooks R, Group E (1996) EuroQol: the current state of play. Health Policy 37(1):53–72

    Article  Google Scholar 

  33. Peasgood T, Herrmann K, Kanis J, Brazier J (2009) An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 20(6):853–868

    Article  CAS  Google Scholar 

  34. Borgström F, Johnell O, Kanis JA, Oden A, Sykes D, Jönsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden. Pharmacoeconomics 22(17):1153–1165

    Article  Google Scholar 

  35. Emrani Z, Sari AA, Zeraati H, Olyaeemanesh A, Daroudi R (2020) Health-related quality of life measured using the EQ-5D–5 L: population norms for the capital of Iran. Health Qual Life Outcomes 18(1):1–8

    Google Scholar 

  36. World Bank Open Data. https://data.worldbank.org/country/iran-islamic-rep. Accessed 2022

  37. World Bank Open Data. https://data.worldbank.org/indicator/PA.NUS.ATLS?locations=IR. Accessed 2022

  38. Dimai HP, Redlich K, Peretz M, Borgström F, Siebert U, Mahlich J (2012) Economic burden of osteoporotic fractures in Austria. Heal Econ Rev 2(1):1–10

    Google Scholar 

  39. International osteoporosis foundation (IOF). Burden of osteoporosis. https://www.osteoporosis.foundation/policy-makers/burden-osteoporosis. Accessed 2020

  40. Aziziyeh R, Perlaza JG, Saleem N, Kirazlı Y, Akalın E, McTavish RK et al (2020) The burden of osteoporosis in Turkey: a scorecard and economic model. Arch Osteoporos 15(1):1–9

    Article  Google Scholar 

  41. Ha Y-C, Kim H-Y, Jang S, Lee Y-K, Kim T-Y (2017) Economic burden of osteoporosis in South Korea: claim data of the national health insurance service from 2008 to 2011. Calcif Tissue Int 101(6):623–630

    Article  CAS  Google Scholar 

  42. Svedbom A, Ivergård M, Hernlund E, Rizzoli R, Kanis JA (2014) Epidemiology and economic burden of osteoporosis in Switzerland. Arch Osteoporos 9(1):1–8

    Article  Google Scholar 

  43. Singer A, Exuzides A, Spangler L, O’Malley C, Colby C, Johnston K et al (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90(1):53–62

    Article  Google Scholar 

  44. Ahmadi-Abhari S, Moayyeri A, Abolhassani F (2007) Burden of hip fracture in Iran. Calcif Tissue Int 80(3):147–153

    Article  CAS  Google Scholar 

  45. Caeiro JR, Bartra A, Mesa-Ramos M, Etxebarría Í, Montejo J, Carpintero P et al (2017) Burden of first osteoporotic hip fracture in Spain: a prospective, 12-month, observational study. Calcif Tissue Int 100(1):29–39

    Article  CAS  Google Scholar 

  46. Major G, Ling R, Searles A, Niddrie F, Kelly A, Holliday E et al (2019) The costs of confronting osteoporosis: cost study of an Australian fracture liaison service. JBMR plus 3(1):56–63

    Article  Google Scholar 

  47. Hoang-Kim A, Kanengisser D (2020) Developing registries and effective care models for the management of hip fractures: aligning political, organizational drivers with clinical outcomes. Curr Osteoporos Rep 18(3):180–188

    Article  Google Scholar 

Download references

Funding

This study was funded by the Tehran University of Medical Sciences (grant number 9611119004).

Author information

Authors and Affiliations

  1. Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Afshin Ostovar & Noushin Fahimfar

  2. Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

    Abdoreza Mousavi & Rajabali Daroudi

  3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Sayed Mahmoud Sajjadi-Jazi & Bagher Larijani

  4. Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Sayed Mahmoud Sajjadi-Jazi

  5. Bushehr University of Medical Sciences, Bushehr, Iran

    Marzieh Rajabi

Authors
  1. Afshin Ostovar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdoreza Mousavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sayed Mahmoud Sajjadi-Jazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marzieh Rajabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bagher Larijani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Noushin Fahimfar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rajabali Daroudi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Noushin Fahimfar or Rajabali Daroudi.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the ethics committee of the Deputy of Research and Technology of the Tehran University of Medical Sciences (IR.TUMS.EMRI.REC.1396.0016). All authors confirm and declare that this study was conducted in compliance with the Declaration of Helsinki. The participants were assured that their information would remain confidential. Informed consent was obtained from all individual participants included in the study.

Conflicts of interest

None.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 101 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ostovar, A., Mousavi, A., Sajjadi-Jazi, S.M. et al. The economic burden of osteoporosis in Iran in 2020. Osteoporos Int 33, 2337–2346 (2022). https://doi.org/10.1007/s00198-022-06484-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-022-06484-x

Keywords

Search

Navigation